LIFE News and Press, aTyr Pharma Inc. From 06/17/20

  Discovery that Neuropilin b1 domain acts as a binding site for SARS-CoV-2 Spike protein and aids viral entry.  Lead therapeutic candidate, ATYR1923, modulates Neuropilin pathway to dampen inflammatory responses. SAN DIEGO, June 17, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc....

ATyr Pharma (NASDAQ: LIFE ) has dosed the first patient in a Phase 2 study evaluating ATYR1923, in hospitalized COVID-19 patients with severe respiratory complications who do not require mechanical ventilation. More news on: aTyr Pharma, Inc., Healthcare stocks news, Read more ....

SAN DIEGO, June 15, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it has dosed the first patient in a Phase 2 study evaluating ...

This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsen’s 13F stock portfolio on a quarterly basis. It is based on Viking Global’s regulatory 13F Form filed on 05/13/2020. Please visit our Tracking Ole Andreas Halvorsen...

SAN DIEGO, May 20, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it will present an abstract in a poster session at the 2020 ...

aTyr Pharma, Inc. (LIFE) Q1 2020 Earnings Conference Call May 12, 2020 17:00 PM ET Company Participants Sanjay Shukla - President and Chief Executive Officer Jill Broadfoot - Chief Financial Officer and Principal Accounting Officer Conference Call Participants Hartaj Singh -...

aTyr Pharma (NASDAQ: LIFE ): Q1 GAAP EPS of $0.25 beats by $0.65 . Revenue of $8.06M beats by $3.66M . Press Release More news on: aTyr Pharma, Inc., Earnings news and commentary, Healthcare stocks news, ,

SAN DIEGO, May 12, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced first quarter results and provided a corporate update. “A...

SAN DIEGO, May 06, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it will report first quarter 2020 financial results and provid...

Abstracts originally accepted for presentation at the 2020 American Thoracic Society (ATS) International Conference Findings confirm that aTyr’s lead clinical candidate, ATYR1923, selectively binds to Neuropilin-2 (NRP2), a unique target expressed on key immune cells in inflamma...